Cytotoxic CD4 T Cells in Bladder Cancer-A New License to Kill.

Cancer Cell

Princess Margaret Cancer Centre, University Health Network, 610 University Ave., Toronto, ON M5G 2M9, Canada; Department of Immunology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. Electronic address:

Published: July 2020

CD4 T cells with cytotoxic capability are increasingly recognized as potentially key actors in anti-tumor immunity. A new report in Cell elucidates the presence and potential role of a population of cytotoxic CD4 T cells in bladder cancer using single cell sequencing technology.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2020.06.013DOI Listing

Publication Analysis

Top Keywords

cytotoxic cd4
8
cd4 t cells
8
cd4 cells
4
cells bladder
4
bladder cancer-a
4
cancer-a license
4
license kill
4
kill cd4
4
t cells cytotoxic
4
cytotoxic capability
4

Similar Publications

Hepatocellular carcinoma (HCC) is characterized by a poor prognosis globally. PAX-interacting protein 1 (PAXIP1) serves a key role in the development of numerous human cancer types. Nevertheless, its specific involvement in HCC remains poorly understood.

View Article and Find Full Text PDF

Death and survival of gut CD4 T cells following HIV-1 infection ex vivo.

PNAS Nexus

November 2024

Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, 12700 E 19th Ave, Mail Stop B168, Aurora, CO 80045, USA.

The gastrointestinal tract is ground zero for the massive and sustained CD4 T cell depletion during acute HIV-1 infection. To date, the molecular mechanisms governing this fundamental pathogenic process remain unclear. HIV-1 infection in the gastrointestinal tract is associated with chronic inflammation due to a disrupted epithelial barrier that results in microbial translocation.

View Article and Find Full Text PDF

The anti-tumor effect of the IFNγ/Fas chimera expressed on CT26 tumor cells.

Anim Cells Syst (Seoul)

January 2025

Department of Biochemistry, College of Natural Sciences, Chungnam National University, Daejeon, Korea.

Interferon gamma (IFNγ) is well-known for its ability to stimulate immune cells in response to pathogen infections and cancer. To develop an effective cancer therapeutic vaccine, CT26 colon carcinoma cells were genetically modified to express IFNγ either as a secreted form (sIFNγ) or as a membrane-bound form. For the membrane-bound expression, IFNγ was fused with Fas (mbIFNγ/Fas), incorporating the extracellular cysteine-rich domains, transmembrane, and cytoplasmic domains of Fas.

View Article and Find Full Text PDF

Introduction: Gallstone may cause complications of cholecystitis, gallbladder gangrene, perforation, and related sepsis. This study aims to identify how CRP and immune cells change in patients with acute calculous cholecystitis based on the severity of disease.

Method: Patients with acute calculous cholecystitis were categorized into three main groups-mild, moderate, and severe-based on the Tokyo guidelines.

View Article and Find Full Text PDF

The Glycopeptide PV-PS A1 Immunogen Elicits Both CD4+ and CD8+ Responses.

Vaccines (Basel)

December 2024

Department of Chemistry and Biochemistry and School of Green Chemistry and Engineering, University of Toledo, 2801 West Bancroft Street, Toledo, OH 43606, USA.

Background/objectives: The MHCII-dependent, CD4+ T-cell zwitterionic polysaccharide PS A1 has been investigated as a promising carrier for vaccine development because it can induce an MHCII-dependent CD4+ response towards a variety of tumor-associated carbohydrate antigens (TACAs). However, PS A1 cannot elicit cytotoxic T lymphocytes through MHCI, which may or may not hamper its potential clinical use in cancer, infectious and viral vaccine development. This paper addresses PS A1 MHCI independence through the introduction of an MHCI epitope, the poliovirus (PV) peptide, to establish an MHCI- and MHCII-dependent vaccine.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!